- Home
- EDIT
EDIT
Editas Medicine Inc.
as 03-25-2025 4:00pm EST
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 108.1M | IPO Year: | 2016 |
| Target Price: | $8.08 | AVG Volume (30 days): | 2.9M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.12 - $7.60 | Next Earning Date: | 03-05-2025 |
| Revenue: | $32,314,000 | Revenue Growth: | -58.64% |
| Revenue Growth (this year): | -72.47% | Revenue Growth (next year): | -9.64% |
Stock Insider Trading Activity of Editas Medicine Inc. (EDIT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lucera Erick | EDIT | EVP, CHIEF FINANCIAL OFFICER | Mar 4 '25 | Sell | $1.71 | 4,109 | $7,029.68 | 112,720 | |
| Burkly Linda | EDIT | EVP, CHIEF SCIENTIFIC OFFICER | Mar 4 '25 | Sell | $1.71 | 2,891 | $4,945.63 | 70,245 | |
| O'Neill Gilmore Neil | EDIT | CEO | Mar 4 '25 | Sell | $1.71 | 16,632 | $28,452.36 | 295,474 |
Latest Editas Medicine Inc. News
EDIT Breaking Stock News: Dive into EDIT Ticker-Specific Updates for Smart Investing
BioPharma Dive
5 days ago
AstraZeneca deepens China investment; Editas loses CFO to Dyne
MT Newswires
6 days ago
Dyne Therapeutics Names Erick Lucera as CFO
GlobeNewswire
6 days ago
Editas Medicine Announces Chief Financial Officer Transition
Simply Wall St.
13 days ago
Here's Why Editas Medicine (NASDAQ:EDIT) Must Use Its Cash Wisely
Zacks
20 days ago
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
Zacks
21 days ago
Editas Medicine (EDIT) Reports Q4 Loss, Misses Revenue Estimates
Associated Press Finance
21 days ago
Editas: Q4 Earnings Snapshot
GlobeNewswire
21 days ago
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
Compare EDIT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EDIT Editas Medicine Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.